Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry

• Published in: Journal of the American Heart Association Vol. 13; no. 10; p. e034493
• Main Authors: Shiyovich, Arthur, Berman, Adam N, Besser, Stephanie A, Biery, David W, Kaur, Gurleen, Divakaran, Sanjay, Singh, Avinainder, Huck, Daniel M, Weber, Brittany, Plutzky, Jorge, Di Carli, Marcelo F, Nasir, Khurram, Cannon, Christopher, Januzzi, James L, Bhatt, Deepak L, Blankstein, Ron
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 21.05.2024; Wiley
• Subjects: acute myocardial infarction; atherosclerotic cardiovascular disease; lipoprotein (a); Original Research; standard modifiable risk factors; atherosclerotic cardiovascular disease; standard modifiable risk factors; acute myocardial infarction; lipoprotein (a)
• ISSN: 2047-9980; 2047-9980
• DOI: 10.1161/JAHA.123.034493

Lipoprotein (a) [Lp(a)] is a robust predictor of coronary heart disease outcomes, with targeted therapies currently under investigation. We aimed to evaluate the association of high Lp(a) with standard modifiable risk factors (SMuRFs) for incident first acute myocardial infarction (AMI). This retrospective study used the Mass General Brigham Lp(a) Registry, which included patients aged ≥18 years with an Lp(a) measurement between 2000 and 2019. Exclusion criteria were severe kidney dysfunction, malignant neoplasm, and prior known atherosclerotic cardiovascular disease. Diabetes, dyslipidemia, hypertension, and smoking were considered SMuRFs. High Lp(a) was defined as >90th percentile, and low Lp(a) was defined as <50th percentile. The primary outcome was fatal or nonfatal AMI. A combination of natural language processing algorithms, ( ) codes, and laboratory data was used to identify the outcome and covariates. A total of 6238 patients met the eligibility criteria. The median age was 54 (interquartile range, 43-65) years, and 45% were women. Overall, 23.7% had no SMuRFs, and 17.8% had ≥3 SMuRFs. Over a median follow-up of 8.8 (interquartile range, 4.2-12.8) years, the incidence of AMI increased gradually, with higher number of SMuRFs among patients with high (log-rank =0.031) and low Lp(a) (log-rank <0.001). Across all SMuRF subgroups, the incidence of AMI was significantly higher for patients with high Lp(a) versus low Lp(a). The risk of high Lp(a) was similar to having 2 SMuRFs. Following adjustment for confounders and number of SMuRFs, high Lp(a) remained significantly associated with the primary outcome (hazard ratio, 2.9 [95% CI, 2.0-4.3]; <0.001). Among patients with no prior atherosclerotic cardiovascular disease, high Lp(a) is associated with significantly higher risk for first AMI regardless of the number of SMuRFs.